Evofem Biosciences annual gross margin
2020
2021
2022
2023
2024
2025
Evofem Biosciences Gross Margin Growth & History (EVFM)
Evofem Biosciences's gross margin was 77.12% for fiscal 2025.
View full Evofem Biosciences company overviewEvofem Biosciences annual gross margin history
| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 77.12% | −3.08 pp |
| 2024 | 2024-12-31 | 80.20% | +15.94 pp |
| 2023 | 2023-12-31 | 64.26% | −9.52 pp |
| 2022 | 2022-12-31 | 73.78% | +22.97 pp |
| 2021 | 2021-12-31 | 50.81% | +55.75 pp |
| 2020 | 2020-12-31 | −4.93% | — |
Evofem Biosciences quarterly gross margin
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 80.59% | −3.76 pp |
| Q1 2026 | 2026-03-31 | 54.39% | −2.41 pp |
| Q4 2025 | 2025-12-31 | 72.89% | −5.83 pp |
| Q3 2025 | 2025-09-30 | 81.72% | +1.05 pp |
| Q2 2025 | 2025-06-30 | 84.35% | +2.84 pp |
| Q1 2025 | 2025-03-31 | 56.80% | −24.21 pp |
| Q4 2024 | 2024-12-31 | 78.72% | −1.57 pp |
| Q3 2024 | 2024-09-30 | 80.67% | +17.62 pp |
| Q2 2024 | 2024-06-30 | 81.51% | +74.80 pp |
| Q1 2024 | 2024-03-31 | 81.02% | +4.70 pp |
| Q4 2023 | 2023-12-31 | 80.29% | +192.44 pp |
| Q3 2023 | 2023-09-30 | 63.05% | −10.58 pp |
| Q2 2023 | 2023-06-30 | 6.71% | −71.99 pp |
| Q1 2023 | 2023-03-31 | 76.31% | +1.39 pp |
| Q4 2022 | 2022-12-31 | −112.15% | −163.00 pp |
| Q3 2022 | 2022-09-30 | 73.63% | +29.41 pp |
| Q2 2022 | 2022-06-30 | 78.70% | +23.88 pp |
| Q1 2022 | 2022-03-31 | 74.92% | +20.72 pp |
| Q4 2021 | 2021-12-31 | 50.84% | +40.72 pp |
| Q3 2021 | 2021-09-30 | 44.22% | +58.25 pp |
| Q2 2021 | 2021-06-30 | 54.82% | — |
| Q1 2021 | 2021-03-31 | 54.21% | — |
| Q4 2020 | 2020-12-31 | 10.12% | — |
| Q3 2020 | 2020-09-30 | −14.03% | — |
Evofem Biosciences gross margin trends
Over the last five fiscal years, Evofem Biosciences's gross margin increased from −4.93% to 77.12%, a change of +82.06 percentage points. The latest reported quarter, Q2 2026, shows 80.59%.
About the metric
What gross margin means
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
Calculation and source
How gross margin is calculated
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Evofem Biosciences source filings ↗